Developing a successful payer strategy has become far more complex than demonstrating clinical efficacy alone. Today’s reimbursement decisions increasingly depend on whether pharmaceutical companies can clearly demonstrate real-world value, address unmet needs, and show how their therapy improves outcomes across the entire care pathway.
An effective payer strategy should be built around real-world patient experiences rather than clinical evidence alone. This is where patient journey insights become a critical strategic asset for pharmaceutical companies.
Yet many organisations continue to build payer strategies using clinical evidence and market research while overlooking one of the most valuable sources of strategic evidence—patient journey insights. As a result, important barriers such as delayed diagnosis, limited treatment access, poor adherence, fragmented care pathways, and unequal healthcare experiences often remain hidden until they begin affecting reimbursement discussions or product uptake.
Without a structured understanding of the patient journey, companies risk developing payer value propositions that fail to address the challenges payers actually prioritise. This can weaken health technology assessment (HTA) submissions, reduce the impact of value dossiers, and make it more difficult to demonstrate the full clinical, economic, and societal value of a therapy. Even highly innovative medicines may struggle to achieve optimal market access when the evidence package does not reflect the realities of patient care.
The good news is that this challenge can be addressed. Organisations that understand how to integrate patient journey insights into payer strategy early in development are better positioned to identify care gaps, generate more relevant evidence, strengthen payer value propositions, and support reimbursement decisions with insights that extend beyond clinical trial data. Rather than treating patient journey mapping as a standalone exercise, leading pharmaceutical companies are embedding these insights throughout their market access strategy to improve both commercial success and patient outcomes.
How pharmaceutical companies should integrate patient journey insights into payer strategy
Successfully integrating patient journey insights into payer strategy requires far more than mapping the patient experience. Pharmaceutical companies need a structured, cross-functional approach that transforms patient insights into evidence that supports reimbursement, HTA, and long-term market access. Rather than treating patient journey mapping as a standalone Medical Affairs activity, organisations should embed it throughout evidence generation, market access planning, health economics and outcomes research (HEOR), and value communication. This ensures that patient experience directly informs the way therapies are positioned for payers and other healthcare decision-makers.
The process should begin with a comprehensive analysis of the patient journey—from the first symptoms and diagnosis through treatment initiation, adherence, long-term management, and follow-up. At every stage, companies should identify barriers that affect outcomes, including delays in diagnosis, inequalities in access, fragmented care pathways, treatment discontinuation, and healthcare resource utilisation. These findings should then be supported with clinical evidence, real-world evidence (RWE), health-economic data, and patient perspectives to create a robust value proposition that reflects both clinical benefit and real-world impact.
Because not every barrier has the same impact on reimbursement decisions, organisations should prioritise patient journey insights according to disease burden, unmet need, economic consequences, and payer relevance. This allows companies to focus evidence generation on the issues that are most likely to influence HTA and reimbursement outcomes.
Equally important is ensuring that patient journey insights are continuously updated throughout the product lifecycle. Healthcare systems, treatment pathways, and payer expectations evolve over time, meaning that evidence generation and payer strategies should evolve alongside them. Companies that systematically integrate patient journey evidence into their strategic planning are better equipped to demonstrate unmet need, address payer priorities, strengthen reimbursement submissions, and ultimately improve patient access to innovative therapies. This proactive approach is becoming increasingly important as organisations seek to understand how to integrate patient journey insights into payer strategy in a way that delivers measurable value for both healthcare systems and patients.
Key stages where patient journey insights create the greatest value for payer strategy
| Stage | What should companies evaluate? |
| Diagnosis | Diagnostic delays |
| Treatment access | Access barriers |
| Treatment | Adherence |
| Follow-up | Outcomes |
| Throughout | Patient voice & RWE |
Successfully integrating patient journey insights also requires close collaboration across Medical Affairs, Market Access, HEOR, Regulatory Affairs, Commercial, and evidence generation teams. Each function contributes unique expertise, but the greatest value is created when patient journey evidence is aligned with shared strategic objectives. This cross-functional approach helps organisations generate consistent evidence, avoid duplication of activities, and ensure that payer strategies are supported by clinically relevant, patient-centred, and economically meaningful data.
How Billev Pharma East helps you transform patient journey insights into a successful payer strategy
Understanding the patient journey is only the first step. The real challenge is turning patient journey insights into evidence that strengthens payer value propositions, supports reimbursement discussions, and ultimately improves patient access. Many pharmaceutical companies have access to clinical data, market research, and stakeholder feedback, but struggle to connect these insights into a coherent strategy that addresses payer expectations. The result is fragmented evidence, missed opportunities to demonstrate value, and weaker market access outcomes.
At Billev Pharma East, we help pharmaceutical companies bridge this gap. Our multidisciplinary team combines expertise in Medical Affairs, regulatory affairs, pharmacovigilance, clinical research, and health economics to translate patient journey insights into practical, evidence-based payer strategies.
Our services include:
• patient journey mapping
• care gap identification
• stakeholder mapping
• patient voice integration
• payer evidence support
• cross-functional strategy workshops
• Medical Affairs support
• evidence generation planning
Rather than treating patient journey mapping as a standalone exercise, we integrate patient insights throughout the product lifecycle—from early evidence generation and care gap identification to stakeholder engagement and value communication. This enables our clients to build stronger payer value propositions that reflect the realities of patient care, not just clinical trial outcomes.
Our approach focuses on four core pillars: understanding the complete patient journey, identifying critical care gaps, integrating the patient voice into strategic decision-making, and improving coordination across healthcare stakeholders. By combining these elements, we help organisations generate evidence that demonstrates clinical, economic, and real-world value while addressing the priorities of payers and healthcare systems. The outcome is a more robust market access strategy, stronger reimbursement submissions, and a clearer pathway to improving both patient outcomes and commercial success.
How to integrate patient journey insights into payer strategy: key success factors
Knowing how to integrate patient journey insights into payer strategy is not simply about collecting patient feedback or creating a visual patient journey map. To influence payer decisions, patient journey insights must be transformed into structured, decision-relevant evidence that demonstrates unmet need, quantifies the impact of current care pathways, and clearly shows how a therapy improves outcomes for both patients and healthcare systems. This requires collaboration across Medical Affairs, Market Access, HEOR, Regulatory Affairs, and evidence generation teams from the earliest stages of product development rather than shortly before launch.
A successful strategy begins by identifying the most important barriers throughout the patient journey—from delayed diagnosis and limited access to treatment through poor adherence, fragmented care coordination, and unnecessary healthcare resource utilisation. These findings should then be supported with clinical evidence, RWE, health-economic analyses, and the patient voice to build a compelling value story that resonates with payers and HTA bodies. Rather than treating each evidence source independently, organisations should create a single, integrated framework that consistently supports reimbursement submissions, value dossiers, stakeholder engagement, and future evidence generation.
Integrating RWE with patient journey insights provides a more comprehensive understanding of how therapies perform outside clinical trials and strengthens the evidence available for payer decision-making.
Finally, patient journey insights should not be viewed as a one-time pre-launch activity. Healthcare pathways, payer expectations, and clinical practice continuously evolve, meaning patient journey analyses should be regularly updated throughout the product lifecycle including pre-launch planning, launch preparation, reimbursement activities and post-launch evidence generation. Companies that continuously refine their evidence strategy are better positioned to demonstrate long-term value, address changing reimbursement requirements, and improve patient access in increasingly complex healthcare environments. By embedding patient journey insights into strategic planning from the outset, pharmaceutical organisations can build payer strategies that are not only scientifically robust but also aligned with the real-world needs of patients and healthcare decision-makers.
Turn patient journey insights into better payer outcomes with Billev Pharma East
As healthcare systems become more evidence-driven and payer expectations continue to evolve, patient journey insights are no longer a “nice to have”—they are becoming a strategic advantage. Pharmaceutical companies that successfully integrate patient journey evidence into payer strategy are better equipped to demonstrate unmet need, strengthen value propositions, support reimbursement discussions, and improve patient access throughout the product lifecycle. Achieving this, however, requires more than collecting data. It requires the ability to translate patient experience into evidence that is meaningful for payers, HTA bodies, and healthcare decision-makers.
At Billev Pharma East, we help pharmaceutical companies do exactly that. By combining expertise in Medical Affairs, Market Access, Regulatory Affairs, Pharmacovigilance, and patient-centric strategy, we transform patient journey insights into practical, evidence-based solutions that support successful payer engagement and market access. Whether you are preparing for launch, strengthening your value proposition, or optimising an established product strategy, our team provides the scientific, regulatory, and strategic expertise needed to turn patient insights into measurable business outcomes.
Companies that successfully integrate patient journey insights into payer strategy are not only better prepared for reimbursement discussions—they also create stronger value propositions, improve stakeholder engagement, reduce market access risks, and position their therapies for long-term success.
Ready to build a stronger payer strategy? Contact Billev Pharma East to discover how our patient-centric expertise can help you generate evidence that improves reimbursement success, accelerates patient access, and creates lasting value for patients, healthcare systems, and your organisation.
Frequently asked questions
What are patient journey insights?
Patient journey insights are evidence-based findings that reveal how patients experience the healthcare pathway—from the first symptoms and diagnosis to treatment, follow-up, and long-term disease management. They help identify barriers, unmet needs, care gaps, and opportunities to improve patient outcomes and healthcare delivery.
Why are patient journey insights important for payer strategy?
Patient journey insights help pharmaceutical companies build stronger payer strategies by demonstrating unmet needs, treatment barriers, real-world outcomes, and the value of a therapy beyond clinical trial data. This enables more compelling value propositions and supports reimbursement and HTA decision-making.
When should patient journey mapping begin?
Patient journey mapping should begin as early as possible during product development—ideally before market access and launch planning. Early generation of patient journey insights allows companies to shape evidence generation, address payer expectations, and strengthen reimbursement strategies throughout the product lifecycle.
Who should be involved in patient journey mapping?
Generating meaningful patient journey insights requires collaboration across Medical Affairs, Market Access, HEOR, Regulatory Affairs, clinical research, and pharmacovigilance, together with healthcare professionals, patients, and other relevant stakeholders. A multidisciplinary approach ensures that patient journey evidence supports both patient needs and payer requirements.
Sources: 1 – European Medicines Agency (EMA). (2022). Engagement framework: European Medicines Agency and patients, consumers and their organisations, 2 – European Medicines Agency (EMA). (2025). Advancing patient-centred access to medicines in partnership with healthcare systems, 3 – European Medicines Agency (EMA). (2025). Patient engagement at EMA: Progressing the concept of patient-centred development into practice, 4 – European Patients’ Academy on Therapeutic Innovation (EUPATI). (2018). Guidance for Patient Involvement in Regulatory Processes, 5 – Medicines and Healthcare products Regulatory Agency (MHRA). (2021). Patient Involvement Strategy 2021–2025.